What happened
BioPharma Dive reported on September 17, 2026, that North Immunology is joining the “sudden spike” in reverse merger deals through an agreement with Aethlon Biotech. The source says North is “armed with $180 million” and a “dual-acting antibody for eczema,” framing the transaction as the startup capitalizing on “a change in sentiment” around reverse mergers. Beyond the parties, the cash figure, the drug description, the indication, and the publication date, the source excerpt does not provide additional deal terms.
Why it matters
The immediate read is less about one eczema program than about financing conditions. If a private biotech with $180 million is choosing a reverse merger path, that suggests the structure is regaining credibility as a route to the public market in 2026, at least for companies with meaningful cash and a lead asset that can be described in relatively clear clinical and commercial terms. That phrase, “change in sentiment,” matters here. Reverse mergers tend to cluster when the market becomes more willing to fund stories that may have struggled to clear the bar in colder periods.
For investors, attention now shifts to the quality of the asset and the durability of that sentiment shift. A dual-acting antibody for eczema gives North a recognizable disease area, but the source excerpt does not spell out development stage, data, or valuation. The harder underwriting questions remain open.
The broader test for the sector: whether 2026’s reverse-merger wave is limited to a few well-capitalized companies or expands into a more durable reopening of biotech public market access. Prior coverage has noted rising interest in alternative paths to market, and this deal fits that pattern. For adjacent coverage on biotech deal flow, see RxNews.ai. For clinical background on drug categories and mechanisms, see ClinicalRx.ai.
